Treatment of HCC with Claudin-1 specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.

[1]  V. Mazzaferro,et al.  Immunotherapies for hepatocellular carcinoma , 2021, Nature Reviews Clinical Oncology.

[2]  N. Almog,et al.  Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. , 2021, Cancer cell.

[3]  R. Schwabe,et al.  Notch activity characterizes a common hepatocellular carcinoma subtype with unique molecular and clinicopathologic features. , 2020, Journal of hepatology.

[4]  E. Nice,et al.  Emerging role of tumor cell plasticity in modifying therapeutic response , 2020, Signal Transduction and Targeted Therapy.

[5]  Kwang-Huei Lin,et al.  Cancer Stem Cell Functions in Hepatocellular Carcinoma and Comprehensive Therapeutic Strategies , 2020, Cells.

[6]  Yulei N. Wang,et al.  Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.

[7]  C. Schuster,et al.  Tight Junction Proteins and the Biology of Hepatobiliary Disease , 2020, International journal of molecular sciences.

[8]  M. Ziol,et al.  Molecular and histological correlations in liver cancer. , 2019, Journal of hepatology.

[9]  D. Brenner,et al.  The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma , 2019, International journal of molecular sciences.

[10]  Pixu Liu,et al.  Patient-derived xenograft mouse models: A high fidelity tool for individualized medicine , 2018, Oncology letters.

[11]  V. Mazzaferro,et al.  Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial , 2018, Gut.

[12]  E. Yu,et al.  Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma , 2018, Journal of experimental & clinical cancer research : CR.

[13]  S. Uemoto,et al.  A novel three-dimensional culture system maintaining the physiological extracellular matrix of fibrotic model livers accelerates progression of hepatocellular carcinoma cells , 2017, Scientific Reports.

[14]  T. Baumert,et al.  Humanisation of a claudin-1-specific monoclonal antibody for clinical prevention and cure of HCV infection without escape , 2017, Gut.

[15]  Lars Kaderali,et al.  Clearance of persistent hepatitis C virus infection using a claudin-1-targeting monoclonal antibody , 2015, Nature Biotechnology.

[16]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[17]  Freddy Radtke,et al.  Regulation of innate and adaptive immunity by Notch , 2013, Nature Reviews Immunology.

[18]  François-Loïc Cosset,et al.  HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. , 2013, Cell host & microbe.

[19]  J. Llovet,et al.  Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. , 2012, Gastroenterology.

[20]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[21]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[22]  J. Zucman‐Rossi,et al.  Hepatocellular carcinoma , 1998, Nature Reviews Disease Primers.